Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres de la Vía Urinaria / Cáncer Ureteral / Recursos de NCI
National Cancer Institute®
Ultima Vez Modificado: 1 de abril del 2002
1
UI - 11534406
AU - Conde Sanchez JM; Espinosa Olmedo J; Rico Lopez J; Camacho Martinez E;
TI -
Blasco Hernandez P; Lara Lara I; Miralles Sanchiz EJ; Garcia Perez M
[Squamous cell carcinoma of the renal pelvis. A clinical case]
SO - Actas Urol Esp 2001 Jul-Aug;25(7):513-8
AD - Servicio de Urologia, Hospital Universitario de Valme, Sevilla.
Squamous cell carcinoma of the renal pelvis is uncommon, accounting for
approximately 10% of all renal pelvic tumours. It's often associated
with chronic renal calculi or infection and it usually presents at an
advanced stage with pain or a palpable mass. We report an incidental
case of squamous cell carcinoma of the renal pelvis, associated with
chronic renal calculi and infection, and weight loss. The prognosis of
patients with advanced squamous cell carcinoma of genitourinary origin
is poor. In patients with chronic stones or infection squamous cell
carcinoma of renal pelvis must be suspected if survival is to be
affected.
2
UI - 11705569
AU - Lord GM; Cook T; Arlt VM; Schmeiser HH; Williams G; Pusey CD
TI -
Urothelial malignant disease and Chinese herbal nephropathy.
SO - Lancet 2001 Nov 3;358(9292):1515-6
We have previously reported occurrence of a specific type of nephropathy
due to ingestion of Chinese herbs (Chinese herbal nephropathy [CHN]) in
two patients in the UK. These cases highlighted the role of aristolochic
acid in causing this nephropathy, which was first described in a Belgian
cohort. We now report development of invasive transitional cell
carcinoma of the urinary tract associated with the presence of
aristolochic acid-DNA adducts in one of these patients. This work
clearly shows the carcinogenic potential of aristolochic acid in this
new type of nephropathy.
3
UI - 11851627
AU - Yang SS
TI -
Primary urethral transitional cell carcinoma in a female.
SO - BJU Int 2001 Dec;88(9):985
4
UI - 11569239
AU - Gilev VN; Stefanov NI; Kaisarov DE
TI -
[Case of urethral cancer in a man]
SO - Urologiia 2001 Jul-Aug;(4):51-2
5
UI - 11905911
AU - Lyon ES; Kyker JS; Schoenberg HW
TI -
Transurethral ureteroscopy in women: a ready addition to the urological
armamentarium. 1978.
SO - J Urol 2002 Feb;167(2 Pt 2):859-60; discussion 861
6
UI - 11706066
AU - Nakanishi K; Hiroi S; Kawai T; Aida S; Kasamatsu H; Aurues T; Ikeda T
TI -
Expression of telomerase catalytic subunit (hTERT) mRNA does not predict
survival in patients with transitional cell carcinoma of the upper
urinary tract.
SO - Mod Pathol 2001 Nov;14(11):1073-8
AD - Division of Environmental Medicine, National Defense Medical College
Research Institute, Tokorozawa 359-8513, Japan. nknsknak@res.ndmc.ac.jp
Telomerase is a ribonucleoprotein enzyme that synthesizes telomeric
repeats onto chromosomal ends using a segment of its RNA component as a
template. Its activity has become an established indicator of the
diagnosis, biological behavior, and prognosis of several tumors.
However, few studies have investigated the diagnostic and prognostic
importance of the expression of telomerase catalytic subunit (hTERT)
mRNA in transitional cell carcinoma of the upper urinary tract
(TCC-UUT). We investigated the expression of hTERT mRNA using in situ
hybridization in 125 cases of TCC-UUT, and also its relation with the
expression of telomerase RNA component (hTERC), proliferating cell
nuclear antigen (PCNA) immunoreactivity, clinicopathologic parameters,
and clinical outcome. A positive expression of hTERT mRNA was recognized
in 93.6% of the samples and was apparent within the cytoplasm of tumor
cells. In the normal urothelium examined in a few cases, its expression
was barely detected. hTERT mRNA scores showed a significant association
with hTERC score. However, no relationship was found between the
expression of hTERT mRNA and clinicopathologic findings, PCNA index, or
prognosis. These results suggest that the expression of hTERT mRNA does
not predict prognosis in TCC-UUT.
7
UI - 11911292
AU - Hirano Y; Kageyama S; Ushiyama T; Suzuki K; Fujita K
TI -
Clinical usefulness of chemotherapy based on an in vitro
chemosensitivity test in urothelial cancer patients.
SO - Anticancer Res 2001 Nov-Dec;21(6A):4061-6
AD - Department of Urology, Hamamatsu University School of Medicine,
Hamamatsu City, Japan. hirano@hama-med.ac.jp
BACKGROUND: We evaluated the clinical usefulness of individualized
chemotherapy based on an in vitro chemosensitivity test, i.e., the
histoculture drug response assay (HDRA), for urothelial cancer.
MATERIALS AND METHODS: 62 clinically obtained cancer specimens were
studied. Each specimen was tested for sensitivity to nine anticancer
drugs. The antitumor effect was calculated as the inhibition rate to
their control values. The HDRA effective cytotoxic drugs were selected
for clinical treatment. RESULTS: HDRA was possible in 58 out of 62
specimens (93.5%). Their chemosensitivity showed a wide variety even
among the same histological category. No correlation was seen between
histological grade and chemosensitivity. The effect of chemotherapy on
the measurable lesions was studied in 12 patients and good clinical
responses were obtained in 7 of them (58.3%). All 7 responders were the
patients who received drugs predicted to be effective by HDRA. In 8 out
of the 12 patients (66.7%), including 7 true-positive and 1
true-negative, HDRA correctly predlicted the clinical effect of
chemotherapy. CONCLUSION: The HDRA might be feasible for predicting the
efficacy and, therefore, selecting the proper anticancer drug for
individual patients.
8
UI - 11847585
AU - Chan V; Pantanowitz L; Vrachliotis TG; Rabkin DJ
TI -
CT demonstration of a rapidly growing transitional cell carcinoma of the
ureter and renal pelvis.
SO - Abdom Imaging 2002 Mar-Apr;27(2):222-3
AD - Department of Radiology, Beth Israel Deaconess Medical Center and
Harvard Medical School, 1 Deaconess Road, Boston, MA 02215, USA.
Transitional cell carcinoma (TCC) is the most common urothelial
malignancy. We present a case of an exceptionally aggressive TCC
involving the renal pelvis and ureter. To our knowledge, an upper tract
TCC of such rapid growth has not been reported.
9
UI - 11555017
AU - Yagi S; Kawano Y; Gotanda T; Kitagawa T; Kawahara M; Nakagawa M; Higashi
TI -
Y
Endoscopic treatment of a long fibroepithelial ureteral polyp.
SO - Int J Urol 2001 Aug;8(8):467-9
AD - Department of Urology, Kagoshima University Hospital, Kagoshima, Japan.
urology@m2.kufm.kagoshima-u.ac.jp
A case is reported of a 30-year-old woman with a long fibroepithelial
polyp in the middle ureter treated with the Ho-YAG laser endoscopically.
She presented with an intermittent macroscopic hematuria and lower
abdominal pain lasting for 1 year. The filling defect on urography
occupying one-third of the ureter was migratory depending on the patient
position. Transurethral flexible ureterorenoscopy showed a large
pedunculated tumor with a small base at the middle ureter. About 1 month
after the endoscopic irradiation of the Ho-YAG laser to the base of
tumor, the tumor was spontaneously discharged and pathologic examination
revealed it to be a fibroepithelial polyp without malignant component.
Postoperatively, the patient remained asymptomatic and follow-up
excretory urographs showed no abnormal findings.
10
UI - 11901541
AU - VanderMolen LA; Sheehy PF; Dillman RO
TI -
Successful treatment of transitional cell carcinoma of the urethra with
chemotherapy.
SO - Cancer Invest 2002;20(2):206-7
AD - Hoag Cancer Center, Newport Beach, CA 92658, USA.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Dr. Mao talks about complementary and alternative medicine and the importance of being open about their use with cancer caregivers. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

